Thermo Fisher Scientific has announced that it has signed an agreement with Cynvenio Biosystems for rights to distribute its LiquidBiopsy platform.

The addition of Cynvenio's rare cell enrichment technology complements Thermo Fisher's Ion Torrent Personal Genome Machine (PGM) workflow and positions the company as the only one in the industry to offer a comprehensive sample-to-genomic data solution for research using a single blood draw for analysis of circulating tumor cells (CTC), cell-free DNA (cfDNA) and normal DNA in less than 48 hours. The workflow enables researchers to conduct highly multiplexed analyses on serially collected blood samples.

Mr André de Fusco, CEO, Cynvenio said, "As a company, we are dedicated to facilitating a new era of individualized medicine. To that end, we see incredible value that our platform and Thermo Fisher's next generations sequencing workflow can bring to translational researchers globally."

"In our evaluation of peripheral monitoring technologies on the market, Cynvenio's LiquidBiopsy platform offers the most compatible addition to our next generation sequencing workflow, particularly as it applies to our evolving oncology strategy. The agreement with Cynvenio also underscores our commitment to provide our oncology research customers with innovative tools to help advance the future of cancer care," said Mr Chris Linthwaite, president, Genetic, Medical and Applied Sciences, Thermo Fisher Scientific.

Cynvenio's liquid biopsy platform as well as the Ion Torrent PGM, Ion Torrent Chef and AmpliSeq Cancer Hot Spot Panel v2 are For Research Use only. Not for use in diagnostic procedures.